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Objectives.T os t u d yt h ec u t - o ﬀ point of Homeostatic Measurement Assessment-Insulin Resistance (HOMA-IR) as a screening test
for detection of glucose intolerance in Thai women with polycystic ovary syndrome (PCOS). Study Design. Cross-sectional study.
Setting.DepartmentofObstetricsandGynecology, FacultyofMedicineSirirajHospital.Subject.TwohundredandﬁftyThaiPCOS
womenwhoattendedtheGynecologicEndocrinologyUnit,duringMay2007toJanuary2009.Materials and Methods.Thepaitents
were interviewed and examined for weight, height, waist circumference, and blood pressure. Venous blood samples were drawn
twice, one at 12-hour fasting and the other at 2 hours after glucose loading. Results. The prevalence of glucose intolerance in Thai
PCOS women was 20.0%. The mean of HOMA-IR was 3.53 ± 7.7. Area under an ROC curve for HOMA-IR for detecting glucose
intolerancewas0.82.Usingthecut-oﬀvalueofHOMA-IR>2.0,therewassensitivityat84.0%,speciﬁcityat61.0%,positivepredic-
tive value at 35.0%, negative predictive value at 93.8%, and accuracy at 65.6%. Conclusion.H O M A - I R>2.0 was used for screening
test for glucose intolerance in Thai PCOS women. If the result was positive, a speciﬁc test should be done to prove the diagnosis.
1.Introduction
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine disorders, aﬀecting around 4–7% of the
population in women of the reproductive age [1]. Diagnostic
criteria for PCOS mostly use the revised Rotterdam 2003
criteria [2]. However, the etiology and pathophysiology of
PCOS remain unclear, and the multiple risk factors such as
genetics, environment, nutrition, lifestyle, and much more
are still under investigation. There is heterogeneity of symp-
toms and in severity of disease but most have central obesity
or android fat deposition (fat at abdominal wall and viscera).
Android fat deposition is relatively resistant to insulin hor-
mone [3, 4]. According to International Diabetes Federation
2005 criteria for metabolic syndrome (IDF 2005) [5], central
obesity is diagnosed when waist circumference is more than
80 centimeters for Asian women. Both of central obesity
and hyperandrogenism in PCOS aggravate insulin resistance
which promotes incidence of diabetes mellitus. Several stud-
ies showed that overall abnormal oral glucose tolerance test
(OGTT) in PCOS is 42–45% which impair glucose tolerance
test 25–31%, and diabetes mellitus 7.5–10%, and all the
abnormalities are associated with age, higher body mass
index (BMI), central obesity, and hyperandrogenemia [6–9].
Acanthosis nigricans is a brown to black, poorly deﬁned,
velvety hyperpigmentation of the skin, usually present in the
posterior and lateral folds of neck, axilla, groin, and other
areas. The most common cause would be insulin resistance2 International Journal of Endocrinology
[10]. By a precisely unknown pathophysiology, it associates
with obesity, and found in PCOS women is about 7.5–
74% [11–13]. Detection of glucose intolerance in PCOS is
achieved by many methods. Hyperinsulinaemic euglycaemic
clamp technique is the gold standard of insulin sensitivity
measurements. However, this technique is very complex
and requires experienced personnel, two intravenous lines
throughout the study, and frequent bedside plasma glucose
determinations, so this technique is not appropriate in
clinical practice [14]. Rotterdam ESHRE/ASRM-sponsor
PCOS Consensus Workshop Group suggests the oral glucose
tolerance test (OGTT) has been traditionally used for the
diagnosis of diatbetes [14], by using 75 gram glucose load
and measure glucose at fasting and 2 hours postloading of
glucose. These diagnostic criteria are followed by American
Diabetes Association (ADA) 2007 [15].
Practically, we have been trying to ﬁnd a solution to
measure insulin resistance by considering the concept that
patients who have insulin resistance will have more insulin
hormone in blood than those who does not. Since insulin
cannot perform its duty well, this causes for higher level
of glucose in blood. Homeostatic Measurement Assessment
Insulin Resistance (HOMA-IR) is an evaluation of insulin
resistance by using glucose level in blood and insulin of
patients while fasting to analysis. This evaluation can be also
used to ﬁnd the insulin resistance which has more advantage
than the 75 gram OGTT that a person who receives the test
is drawn blood only one. It might has beneﬁt for screening.
From the previous studies, there is still no conclusion
about cut-oﬀ point used in diagnosis of insulin resistance.
Matthews et al. used HOMA-IR more than 2.5 for diagnosis
of insulin resistance in general population [16]. Keskin et al.
studiedinpubertalobesechildrenandadolescents;thisstudy
has shown HOMA cut-oﬀ point at 3.16 [17]. Jensterle et al.
used cut-oﬀ point for HOMA-IR of at least 2.0 for diagnosis
of insulin resistance in young PCOS women [18]. Most
studies of HOMA-IR in PCOS women were in American and
Europeanwomen.HOMA-IRdidnothavetheprecisecut-oﬀ
value used in diagnosis of insulin resistance. Therefore, the
objective of this study was to determine the result of using
HOMA-IR as a diagnostic test for detection of abnormal
OGTTinThaiwomenwithPCOS,fordiscoveringtheproper
cut-oﬀ value to diagnose glucose intolerance and getting the
data important for applying in clinical practice.
2.MaterialsandMethods
This cross-sectional study was conducted. Using data is
based on the records of 250 PCOS women who consecu-
tively attended the Gynecologic Endocrinology Unit of the
Department of Obstetrics and Gynecology, Siriraj Hospital
between May 2007 and January 2009, which were reviewed
and analyzed. The diagnosis of PCOS was deﬁned by the
Revised Rotterdam Criteria 2003 [2].
Exclusion criteria included the women who had previous
surgery of one or both ovaries, used hormonal treatment,
and took the medication for dyslipidemia within 3 months
and/or received steroid within 6 months before participation
in the study. The study protocol was approved by the Ethics
Committee of the Faculty of Medicine Siriraj Hospital,
Mahidol University. This study was ﬁnancially supported by
Siriraj Routine to Research (R2R) Management Fund.
All the women with PCOS who participated in this study
received a physical examination including measurement of
vital signs and skin lesions, and anthropometric measure-
ments, as a prelude to a review of clinical presentations. Age,
body weight, height, waist circumference, blood pressure,
and skin manifestations were recorded. After overnight
fasting for at least 12 hours, venous blood samples were
drawn twice, the ﬁrst one at 8–10AM and the second
one at 2-hour postglucose loading to measure glucose and
insulin level at baseline and 2 hours following oral 75g
glucose loading. The ﬁrst blood sample was also examined
for baseline hormonal proﬁles (prolactin, cortisol, thyroid
stimulating hormone (TSH), and androgen hormone) and
baseline metabolic proﬁle (glucose, insulin, and lipid). The
second blood sample was examined for glucose and insulin
postglucose loading.
2.1. Diagnostic Criteria. PCOS was diagnosed by the Revised
Rotterdam Criteria 2003 [2], that is, including a patient who
has at least 2 in 3 of the following: (1) oligomenorrhea
or amenorrhea, (2) hyperandrogenemia and/or hyperandro-
genism, (3) polycystic ovaries, and excluding another causes
(e.g., hyper/hypothyroidism, hyperprolactinemia, Cushing’s
syndrome, congenital adrenal hyperplasia (CAH), or hor-
monal secreting tumor).
Glucose tolerance was evaluated using 75g OGTT
according to the American Diabetes Association (ADA)
2007 criteria [15]. Abnormal OGTT is classiﬁed as follows:
(i) impaired fasting glucose (IFG), that is, fasting glucose
(FG) ≥100 and <126mg/dL, (ii) impaired glucose tolerance
test (IGT), that is, 2hr glucose ≥140 and <200mg/dL, (iii)
type 2 Diabetes mellitus (DM), that is, fasting blood glu-
cose ≥126mg/dL and/or 2hr glucose ≥200mg/dL. In our
study, glucose intolerance was composed of IFG, IGT, and
Type 2 DM.
The HOMA-IR was calculated by multiplying fasting
Insulin (U/mL) by fasting glucose (mmol/L) and dividing by
22.5.
Obesity was deﬁned as body mass index (BMI) ≥25kg/
m2 according to the WHO cut-oﬀ points for Asian pop-
ulations [19]. Central obesity was deﬁned as WC ≥80cm
according to the International Diabetes Federation (IDF)
2005 [5].
Hyperandrogenemia was deﬁned as total testoster-
one >0.8ng/mL, or free testosterone >0.006ng/mL, or dehy-
droepiandrosterone sulphate (DHEAS) >350 microgram/dL
[20].
2.2. Laboratory Assays. All laboratory assays were performed
at the laboratory unit of Department of Clinical Pathology,
Faculty of Medicine Siriraj Hospital, Mahidol University, the
central laboratory certiﬁed by IS0 15189. All assays were
done using an automatic analyzer (Modular P800, Roche;
for glucose and Modular E170, Roche; for insulin, TSH,International Journal of Endocrinology 3
Table 1: Characteristics of 250 PCOS Thai women.
Characteristics Mean ± SD or
n (%, 95% CI)
Age (yr) 25.4 ±5.8
Body mass index (kg/m2)2 6 .2 ±7.6
Waist circumference (cm) 82.3 ±16.3
Systolic blood pressure (mmHg) 112.5 ±12.5
Diastolic blood pressure (mmHg) 70.3 ±9.1
Presence of acanthosis nigricans 68 (27.2, 21.7–32.7)
Carbohydrate metabolism
Fasting plasma glucose (mg/dL) 85.4 ±22.9
Fasting plasma insulin (mu/mL) 15.6 ±34.2
2 hour plasma glucose (mg/dL) 116.4 ±53.8
2 hour plasma insulin (mu/mL) 106.6 ±89.0
HOMA-IR 3.53 ±7.74
Lipid proﬁles
Cholesterol (mg/dL) 189.2 ±37.6
Triglyceride (mg/dL) 103.2 ±66.2
High density lipoprotein cholesterol (mg/dL) 55.4 ±14.6
Low density lipoprotein cholesterol (mg/dL) 112.0 ±32.5
Androgen proﬁles
Total testosterone (ng/mL) 0.735 ±0.388
Free testosterone (ng/mL) 0.014 ±0.009
DHEAS (microgram/dL) 256.8 ±107.2
HOMA-IR: Homeostatic Measurement Assessment-Insulin Resistance,
DHEAS: dehydroepiandrosterone sulphate.
prolactin, cortisol). All techniques had intra- and interassay
coeﬃcients of variation (CV) less than 5%.
2.3. Statistical Analysis. Statistical analysis was performed
using SPSS version 13 (SPSS Inc.). Data were presented in
mean ± SD or number (%) as appropriate. The sensitivity
speciﬁcitypositivepredictivevalue,negativepredictivevalue,
and diagnostic accuracy were calculated from 2 × 2 tables
for HOMA-IR at each cut-point for detection of abnormal
OGTT. Receiver operator curves (ROCs) for HOMA-IR and
abnormal OGTT were created by calculating the sensitivity
a n ds p e c i ﬁ c i t yo fﬁ x e dc u t - o ﬀ points of the various parame-
ters examined.
3. Results
A total of 250 women with PCOS were studied. The clinical
and laboratory characteristics were summarized in Table 1.
The mean age, BMI, and waist circumference (WC) were
25.4 ± 5.8 years old, 26.2 ± 7.6kg/m2 and 82.3 ± 16.3cm,
respectively. The diagnostic criteria of PCOS were 98.4%
of oligomenorrhea, 49.2% of hyperandrogenism, and 97.2%
of polycystic ovaries. In this study 27.2% had acanthosis
nigricans. The blood level of carbohydrate metabolic proﬁles
showedthefastingbloodglucosewas85.4 ±22.9mg/dL,2hr
blood glucose was 116.4 ± 53.8mg/dL, fasting insulin was
Table 2: Prevalence of glucose intolerance in 250 Thai women with
polycystic ovary syndrome.
Glucose intolerance† Prevalence
n % (95% CI)
Overall 50 20.0 (15.04–24.96)
Impaired fasting glucose (IFG)‡ 8 3.2 (1.02–5.38)
Impaired glucose tolerance (IGT) 34 13.6 (9.35–17.85)
Diabetes mellitus (DM) 14 5.6 (2.75–8.45)
†Glucoseintolerance:impairedfastingglucose(fastingplasmaglucose ≥100
and <126mg/dL), impaired glucose tolerance test (2hr glucose ≥140 and
<200mg/dL) or the presence of diabetes mellitus (fasting plasma glucose
≥126mg/dL and/or 2hr glucose ≥200mg/dL).
‡4womenhadcombinedIFGandIGTand2womenhadcombinedIFGand
2hrglucose≥200mg/dL.
Table 3: Sensitivity, speciﬁcity, positive predictive value, negative
predictive value and accuracy of HOMA-IR >2.0 for detection of
glucose intolerance in Thai PCOS women.
Parameter Percent (%) 95% CI
Sensitivity 84.0 79.5–88.5
Speciﬁcity 61.0 55.0–67.1
Positive predictive Value 35.0 29.1–40.9
Negative Predictive Value 93.8 91.1–96.9
Accuracy 65.6 60.1–71.9
15.6 ± 34.2mu/mL, 2hr insulin was 106.6 ± 89.0mu/mL,
and HOMA-IR was 3.53 ± 7.74.
The prevalence of an glucose intolerance is shown in
Table 2. An glucose intolerance was found in 20.0%, with
5.6% having type 2 diabetes mellitus, 3.2% having impaired
fasting glucose levels, and 13.6% having an impaired glucose
tolerance test.
Figure 1 showed ROC curve of HOMA-IR and glucose
intolerance. The area under the curve was 0.82.
Sensitivity, speciﬁcity, positive predictive value, negative
predictive value, and accuracy of the cut-oﬀ HOMA-IR of
more than 2.0 for detection of glucose intolerance in PCOS
women were 89.74%, 58.82%, 38.46%, 95.24%, and 65.71%,
respectively, as in Table 3.
Table 4 shows the relation between associating factors of
glucose intolerance in PCOS and HOMA-IR >2.0. All had
statistical signiﬁcance with HOMA-IR >2.0. Odds ratio for
age ≥30 = 2.45, BMI ≥25 = 23.37, WC ≥80cm = 24.55,
hyperandrogenism = 1.97, and presence of acanthosis nigri-
cans = 50.03.
Usingcut-oﬀpointHOMA>2.0andthenumberofclini-
calassociating factorfor insulin resistance,odds ratio in each
condition is shown in Table 5. The signiﬁcant odds ratio
included the conditions of HOMA >2.0 combined with 4
clinical associating factors and HOMA >2.0 combined with
5 clinical associating factors; odds ratio (95% CI) were 2.67
(1.31–5.42) and 9.75 (3.16–30.10), respectively.4 International Journal of Endocrinology
Table 4: Relation of HOMA-IR and associating factors of glucose intolerance.
Variables HOMA-IR ≤2H O M A - I R >2 Odds ratio 95% CI
n (%) n (%) odds ratio
Age (years old) 2.45 1.33–4.53
<30 110 (57.0) 83 (43.0)
≥30 20 (35.1) 37 (64.9)
BMI (kg/m2) 23.37 12.07–45.26
<25 111 (82.2) 24 (17.8)
≥25 19 (16.5) 96 (83.5)
Waist circumference (cm) 24.55 12.64–47.67
<80 108 (84.4) 20 (15.6)
≥80 22 (18.0) 100 (82.0)
Hyperandrogenism 1.97 1.19–3.26
No 76 (60.3) 50 (39.7)
Yes 54 (49.3) 70 (56.5)
Acanthosis nigricans 50.03 15.07–166.08
Absent 127 (69.8) 55 (30.2)
Present 3 (4.4) 65 (95.6)
Table 5: Odds ratio in each condition which showed HOMA >2.0 with number of clinical associating factors.
Condition n (%) OR (95% CI) P value
HOMA >2.0 with 1 clinical associating factor 2 (0.8) 0.79 (0.74–0.85) 0.219
HOMA >2.0 with 2 clinical associating factors 6 (2.4) 1.10 (0.42–2.89) 0.805
HOMA >2.0 with 3 clinical associating factors 11 (4.4) 1.97 (0.89–4.35) 0.113
HOMA >2.0 with 4 clinical associating factors 16 (6.4) 2.67 (1.31–5.42) 0.008
HOMA >2.0 with 5 clinical associating factors 20 (8.0) 9.75 (3.16–30.10) <0.001
Clinical associating factors are age ≥30 year old, BMI ≥25kg/m2, waist circumference ≥80 centimeters, presence of acanthosis nigricans, and hyperandrog-
enism.
4. Discussions
Insulin resistance and the consequent development of hyper-
insulinemia seem to be an important pathophysiological
mechanism that links PCOS to its concurrent metabolic
derangements [1]. An insulin resistance is due to alterations
in β-cell function, it might have a key role in the impaired
glucose tolerance test and the development of frank diabetes
in women with PCOS. It is well known that type 2 DM is an
important risk factor for coronary heart disease. In previous
studies, type 2 DM was found to contribute signiﬁcantly to
the mortality of women with PCOS (odds ratio 3.6; 95%
conﬁdenceinterval1.5–8.4)morethanthatexpectedinunaf-
fected women [21]. In this study, our data indicated that the
prevalence of abnormal glucose tolerance in our study was
lower than that of American women with PCOS but similar
to that of Chinese women with PCOS [22]. According to
some,diﬀerencesamongthesestudiesintheselectioncriteria
of PCOS cannot be ignored and the factors of ethnic back-
ground, dietary composition, and lifestyle might play an
important role in the prevalence of abnormal glucose toler-
ance in women with PCOS.
Therefore, an OGTT is currently the only reliable way to
detect impaired glucose metabolism in PCOS. This proce-
dure is relatively time-consuming and inconvenient for the
patient,whichlimitsitsuseasageneralscreeninginstrument
in daily practice. Therefore, a more convenient screening test
that minimizes the need for an OGTT is desirable. In this
study, HOMA-IR had the close relation for detection of
abnormal OGTT in Thai PCOS women. If using the cut-oﬀ
levelofHOMA-IR>2.0fordetecting theglucoseintolerance,
it can give more sensitivity, but speciﬁcity was less than the
higher cut-oﬀ level. It may be suitable for use as a screening
test for detecting of glucose intolerance or insulin resistance
in Thai PCOS women. In the cases which had a false
positive test, if they received the treatment to control insulin
intolerance, it did not have a serious eﬀect on the treatment.
Because the early step of treatment is life style modiﬁcation,
control of body weight, control of diet and exercise, these
methods are the better way for controlling other metabolic
disorders, too. Insulin sensitizing drug for example, met-
formin, provides beneﬁt to control insulin resistance in
PCOS women. Nevertheless this drug would give minor gas-
trointestinal side eﬀect and no serious adverse event was
reported [23].
Many studies use the HOMA-IR as the diagnostic criteria
for insulin resistance [2,17,18,24]. TheEuropean Group for
the Study of Insulin Resistance (EGIR) uses the cut-oﬀ level
of HOMA-IR >2.0 to indicate insulin resistance or glucose
intolerance [24]. Some studies used diﬀerent cut-oﬀ levels ofInternational Journal of Endocrinology 5
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Figure 1: ROC curve for HOMA-IR for detecting glucose intoler-
ance in Thai PCOS women. The area under the curve is 0.82.
HOMA-IR, because of the diﬀerences of each ethnic group,
the prevalence of obesity or central obesity or age group.
Andnoconsensusonthecut-oﬀlevelofHOMA-IRexistsfor
Thai PCOS women. A screening strategy that uses BMI and
waist circumference, which is a low-cost and rapidly per-
formed approach, could save about 23% of OGTT [25].
However, if PCOS women have the risk factors to develop
insulin resistance, the diagnostic procedure should be done.
Many studies showed clinical risk factors of glucose
intolerance in PCOS: age, BMI, central obesity, hyperan-
drogenism, presence of acanthosis nigricans [6–9, 26–28].
Table 4 shows a statistical relation between HOMA-IR >2.0
and these factors. If PCOS women presented clinical risk
factor and had abnormal HOMA-IR, especially 4 and 5
clinical risks, these women would have a signiﬁcant odds
r a t i ot oh a v eg l u c o s ei n t o l e r a n c e( Table 5). On the other
hand, we can use the clinical risk to select high risk women
forinvestigationofaspeciﬁctestforglucoseintolerance(75g
OGTT).
Limitations of this study were that it was cross-sectional
study and had no control group. The majority of population
in this study was younger and was an urban population; this
mightnotbeabletofullyrepresentallThaiPCOSwomen.To
overcome these limitations, a prospective, multicenter study
is needed.
5. Conclusion
HOMA-IR was an easily obtainable, safe, low cost, and less
invasive test than OGTT. HOMA-IR >2.0 was used as a
screening test for glucose intolerance in Thai PCOS women.
If the result was positive and had many clinical risk factors, a
speciﬁc test should be done to prove the diagnosis.
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